Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04852081
Other study ID # 01-2021
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date December 1, 2021

Study information

Verified date April 2021
Source Blokhin's Russian Cancer Research Center
Contact Vera Karaseva
Phone +7 (499) 686-02-37
Email Karaseva@russco.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A assessment of the efficacy of first-/second-line endocrine therapies ± target therapies and chemotherapy in real-life of in patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer has not yet been conducted in Moscow. Methods: Observational, retrospective study carried out in oncology hospitals in Moscow, in patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer. The descriptive analysis will be conducted for patient characteristics, responses to treatment and treatment outcomes. This study will provide retrospective chart review of evidence on the use of therapy in routine clinical practice, with a focus in population of Moscow


Description:

The combination CDK4/6 inhibitors (CDK4/6i) (Palbociclib, Ribociclib and Abemaciclib) with endocrine therapy (ET, i.e. aro- matase inhibitors (AI) or Fulvestrant) has significantly increased objective response rate (ORR) and progression-free survival (PFS) of first- and second-line treatments in patients with hormone receptor positive, HER2 negative (luminal) mBC. Now this combination is the standard treatment for luminal mBC. Recommendation for endocrine therapy versus chemotherapy as first-line treatment of luminal mBC is endorsed by the main international guidelines such as ASCO and ESO-ESMO guidelines. Endocrine therapy should be used as initial treatment except in cases of immediately life-threatening disease, tumors refractory to endocrine therapy, visceral crisis, or rapid progressive disease that mandate a high response rate treatment. The aim of this study is to provide real-life treatment patterns data for luminal MBC with a focus in population of Moscow


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date December 1, 2021
Est. primary completion date December 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer based on the most recently analyzed tissue sample and all tested by local laboratory. ER should be more than 10% ER positive or Allred =5 by local laboratory testing. - Patient has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing and based on the most recently analyzed tissue sample. - Patient has inoperable locally advanced or metastatic breast cancer - Patient has adequate bone marrow and organ function - Patient must be physically well enough that they are capable of treatment Exclusion Criteria: - Patient has severe acute or chronic medical or psychiatric condition, including recent or active suicidal ideation or behavior, or laboratory abnormality that may interfere with the interpretation of study results - no clinical and anamnestic information or information about safety or information about effectiveness treatment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Palbociclib
Palbociclib is in the form of oral capsules. Palbociclib, capsule, 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food
Ribociclib
Ribociclib, tablets, 600mg orally (three 200 mg tablets)taken once daily with or without food for 21 consecutive days followed by 7 days off treatment
Abemaciclib
Abemaciclib in combination with fulvestrant or an aromatase inhibitor: 150 mg twice daily Abemaciclib as monotherapy: 200 mg twice daily. (2.1)
Letrozole
Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
Anastrozole
Anastrozole will be dosed daily at a fixed dose of 1 mg/day throughout the study.
Tamoxifen
Tamoxifen will be dosed daily at a fixed dose of 20 mg/day throughout the study.
Fulvestrant
Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
Exemestane
Exemestane will be dosed daily at a fixed dose of 25mg/day throughout the study.
Alpelisib
Alpelisib will be dosed daily at a fixed dose of 300 mg/day throughout the study.

Locations

Country Name City State
Russian Federation N.N. Blokhin National Medical Research Center of Oncology Moscow

Sponsors (1)

Lead Sponsor Collaborator
Blokhin's Russian Cancer Research Center

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary To describe treatment sequences of all lines of therapy received by HER2 + mBC patients in Moscow The proportion of each type of treatment received for all lines of therapy in the metastatic setting will be determined. 12 months
Secondary Proportion of patients among study population who have with symptomatic visceral metastasis Proportion of patients among study population who have with symptomatic visceral metastasis 12 months
Secondary Proportion of patients among study population who have treatment-emergent Adverse Events Proportion of patients among study population who have treatment-emergent Adverse Events 12 months
Secondary Proportion of premenopausal women among study population Proportion of premenopausal women among study population 12 months
Secondary percentage of obtaining tumor specimens and reevaluating targeted markers in breast cancer patients who relapsed after curative treatment percentage of obtaining tumor specimens and reevaluating targeted markers in breast cancer patients who relapsed after curative treatment 12 months
Secondary Proportion of patients among study population who have visceral metastasis Proportion of patients among study population who have visceral metastasis 12 months
Secondary Evaluation of the outcome per treatment line To evaluate the outcome of patients per treatment line (objective response, progression free survival, time to disease progression per line of therapy), overall survival 12 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04469127 - A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients. Phase 1/Phase 2
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Terminated NCT04123704 - Sitravatinib in Metastatic Breast Cancer Phase 2
Recruiting NCT05377047 - Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer N/A
Completed NCT03304210 - PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer Phase 1
Completed NCT05054374 - A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT05559528 - BRaziLian outcomE for metAStatic breasT Cancer
Active, not recruiting NCT05090358 - Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer Phase 2
Recruiting NCT05033925 - Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients Phase 1/Phase 2
Recruiting NCT03401359 - The Resistance and Immune Response to Palbociclib in Breast Cancer N/A
Active, not recruiting NCT03870919 - Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients N/A
Not yet recruiting NCT05860907 - Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis Phase 4
Completed NCT00393341 - Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer N/A
Recruiting NCT05625087 - Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib Phase 2
Completed NCT04566458 - RWD Study in HER2+ mBC Patients in Third-Line Therapy
Recruiting NCT06075810 - A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer Phase 1
Recruiting NCT04697043 - The Benefit of Surgery in Stage IV of Breast Cancer N/A
Recruiting NCT05837533 - Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients N/A
Active, not recruiting NCT03324425 - Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer Phase 2
Recruiting NCT05670054 - Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients Phase 3